<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548391</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0070</org_study_id>
    <nct_id>NCT01548391</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotoxtech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotoxtech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, and pharmacokinetics of HX-1171
      in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (normal results for safety tests)</measure>
    <time_frame>14days</time_frame>
    <description>Physical examination, Vital signs</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HX-1171 20 mg (20mg 1T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HX-1171 40 mg (20mg 2T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HX-1171 80 mg (20mg 4T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HX-1171 160 mg (20mg 8T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HX-1171 300 mg (200mg 1T, 20mg 5T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HX-1171 600 mg (200mg 3T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HX-1171 1200 mg (500mg 2T, 200mg 1T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HX-1171 1500 mg (500mg 3T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HX-1171 2000 mg (500mg 4T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HX-1171</intervention_name>
    <description>20mg, 200mg, 500mg</description>
    <arm_group_label>HX-1171 20 mg (20mg 1T)</arm_group_label>
    <arm_group_label>HX-1171 40 mg (20mg 2T)</arm_group_label>
    <arm_group_label>HX-1171 80 mg (20mg 4T)</arm_group_label>
    <arm_group_label>HX-1171 160 mg (20mg 8T)</arm_group_label>
    <arm_group_label>HX-1171 300 mg (200mg 1T, 20mg 5T)</arm_group_label>
    <arm_group_label>HX-1171 600 mg (200mg 3T)</arm_group_label>
    <arm_group_label>HX-1171 1200 mg (500mg 2T, 200mg 1T)</arm_group_label>
    <arm_group_label>HX-1171 1500 mg (500mg 3T)</arm_group_label>
    <arm_group_label>HX-1171 2000 mg (500mg 4T)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males aged 20 to 40 years at screening.

          -  Be able to comply with the requirement of the study. Subject must provide written
             informed consent prior to study participation.

        Exclusion Criteria:

          -  History or presence of liver, kidney, or nervous system disease, respiratory
             disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric
             or gastrointestinal disorders.

          -  History of known hypersensitivity to drugs including HX-1171.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
      <phone>82-2-3010-4611</phone>
      <email>ksbae@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://crc.amc.seoul.kr</url>
    <description>Clinical Research Center, Asan Medical Center</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

